Wagner-Drouet Eva, Teschner Daniel, Wolschke Christine, Schäfer-Eckart Kerstin, Gärtner Johannes, Mielke Stephan, Schreder Martin, Kobbe Guido, Hilgendorf Inken, Klein Stefan, Verbeek Mareike, Ditschkowski Markus, Koch Martina, Lindemann Monika, Schmidt Traudel, Rascle Anne, Barabas Sascha, Deml Ludwig, Wagner Ralf, Wolff Daniel
Department of Hematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Eppendorf, Hamburg, Germany.
Diagnostics (Basel). 2021 Feb 15;11(2):312. doi: 10.3390/diagnostics11020312.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT). Measuring CMV-specific cellular immunity may improve the risk stratification and management of patients. IFN-γ ELISpot assays, based on the stimulation of peripheral blood mononuclear cells with CMV pp65 and IE-1 proteins or peptides, have been validated in clinical settings. However, it remains unclear to which extend the T-cell response to synthetic peptides reflect that mediated by full-length proteins processed by antigen-presenting cells. We compared the stimulating ability of pp65 and IE-1 proteins and corresponding overlapping peptides in 16 HSCT recipients using a standardized IFN-γ ELISpot assay. Paired qualitative test results showed an overall 74.4% concordance. Discordant results were mainly due to low-response tests, with one exception. One patient with early CMV reactivation and graft-versus-host disease, sustained CMV DNAemia and high CD8 counts showed successive negative protein-based ELISpot results but a high and sustained response to IE-1 peptides. Our results suggest that the response to exogenous proteins, which involves their uptake and processing by antigen-presenting cells, more closely reflects the physiological response to CMV infection, while the response to exogenous peptides may lead to artificial in vitro T-cell responses, especially in strongly immunosuppressed patients.
巨细胞病毒(CMV)感染是造血干细胞移植(HSCT)后发病和死亡的主要原因。检测CMV特异性细胞免疫可能会改善患者的风险分层和管理。基于用CMV pp65和IE-1蛋白或肽刺激外周血单个核细胞的IFN-γ ELISpot检测已在临床环境中得到验证。然而,尚不清楚T细胞对合成肽的反应在多大程度上反映了由抗原呈递细胞加工的全长蛋白介导的反应。我们使用标准化的IFN-γ ELISpot检测比较了16例HSCT受者中pp65和IE-1蛋白以及相应重叠肽的刺激能力。配对的定性检测结果显示总体一致性为74.4%。不一致的结果主要是由于低反应性检测,只有一个例外。一名患有早期CMV再激活和移植物抗宿主病、持续CMV血症和高CD8计数的患者,基于蛋白的ELISpot检测结果连续为阴性,但对IE-1肽有高且持续的反应。我们的结果表明,对外源蛋白的反应涉及抗原呈递细胞对其摄取和加工,更能密切反映对CMV感染的生理反应,而对外源肽的反应可能导致人为的体外T细胞反应,尤其是在免疫抑制严重的患者中。